Why the study?
Default DAPT after ACS and PCI is challenged by controversies over aspirin's role, optimal DAPT duration, P2Y12 inhibitor choice, and variability in individual drug responses.
Does personalized antiplatelet therapy improve ischemic and bleeding outcomes in patients after acute coronary syndrome and percutaneous coronary intervention?
Does personalized antiplatelet therapy improve ischemic and bleeding outcomes in patients after acute coronary syndrome and percutaneous coronary intervention?
The paper highlights the need to move away from a default one-size-fits-all DAPT strategy towards personalized antiplatelet therapy in post-ACS and PCI patients to balance ischemic and bleeding risks.
Answers are grounded in this paper and cite their sources.
P2Y12 monotherapy should not yet replace DAPT; leaves open whether personalized regimens improve net outcomes post-ACS/PCI.
Cardiovascular disease is the leading cause of death worldwide. Dual antiplatelet therapy (DAPT), with aspirin plus a P2Y12 inhibitor, is currently recommended as a default for patients after acute coronary syndrome (ACS) and following percutaneous coronary intervention (PCI). However, controversies arise over the role of aspirin, the optimal duration of DAPT after drug-eluting stent (DES) implantation, the choice of P2Y12 inhibitor and the variability in individual responses to antiplatelet agents. Recent data indicate that monotherapy with a P2Y12 inhibitor may have adequate anti-ischemic effects with lower bleeding risk. Additionally, discrepancies in DAPT duration recommendations and the optimal P2Y12 inhibitor, provides more uncertainty. We ask the question "does one size really fits all?" or should a more personalized strategy should be implemented.
No takes yet. Share an insight, caveat, or question.
Elserwey et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: